2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 323

Effect of 10 Years of Denosumab Treatment on Bone Histology and Histomorphometry in the Freedom Extension Study

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 268

Effect of Abatacept Treatment on T Cells in Muscle Tissue and Peripheral Blood in Polymyositis and Dermatomyositis Patients

Muscle Biology, Myositis and Myopathies - Poster I: Basic/Translational

9:00AM-11:00AM: Abstract Number: 394

Effect of BMI on Symptoms and Outcomes in Juvenile Idiopathic Arthritis Patients

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis

9:00AM-11:00AM: Abstract Number: 372

Effect of Chronicity on Pain Behaviors in Collagenase Induced Non-Inflammatory Monoarthritis in Mice

Pain – Basic and Clinical Aspects - Poster

9:00AM-11:00AM: Abstract Number: 772

Effect of HMG-CoA Reductase Inhibitor Drugs (Statins) on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 621

Effectiveness and Safety of CT- P13 (Biosimilar Reference Infliximab) in a Real-Life Setting in 151 Patients with Rheumatoid Arthritis and Ankylosing Spondylitis: A Mid-Term Interim Analysis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 378

Effects of a Natural Product Containing Specialized Pro-Resolving Mediators in Subjects with OA, RA, or Other Chronic Inflammatory Conditions in a Multi-Clinic Case Series

Pain – Clinical Aspects - ARHP Poster

9:00AM-11:00AM: Abstract Number: 9

Effects of Alcohol Consumption on the Severity of Inflammation in Hand and Foot Joints Detected with MR Imaging

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 97

Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled Retro- Study

Health Services Research - Poster I

9:00AM-11:00AM: Abstract Number: 727

Effects of Nsaids on Disease Activity in Ankylosing Spondylitis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 349

Effects of Osteoporosis Treatments for Bone Loss and Pain-Related Behavior in the Hind Limb-Unloaded Mouse Model of Disuse Osteoporosis

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 39

Effects of Pregabalin (Lyrica®) on Cerebrospinal Fluid Substance P in Human Subjects with Fibromyalgia Syndrome

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster I: Basic Science Focus

9:00AM-11:00AM: Abstract Number: 760

Effects of Type I Interferon Inhibition on Blood Leukocyte Subsets in Patients Treated in a Phase IIb Clinical Study of Anifrolumab in SLE

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 622

Efficacy after Transition to SB5 from Reference Adalimumab (Humira®) Vs. Continuation of SB5 or Reference Adalimumab By Antibodies Developed after Transition from a SB5 Phase III Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 692

Efficacy and Safety of Biological Therapy and Target Synthetic Dmards: A Systematic Literature Review Informing the 2016 Update of the ASAS/EULAR Recommendations for the Management of Axial Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].